Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.10.1 (
ERK
)
95,504
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
BCG immunotherapy often has severe complications in cancer patients despite lack of toxicity in the immunocompetent individual.
MER
, a cell wall fraction of BCG, has been reported to cause immunopotentiation similar to that of BCG without equivalent toxicity. Recently, animal models have been reported to develop
MER
complications, especially disseminated granuloma formation, like those of BCG. For the past several years,
MER
has been used as adjuvant immunotherapy for treatment of malignant tumors with minimal systemic toxicity reported. A patient with malignant melanoma was treated with intralesional
MER
at the site of local metastases. He developed military pulmonary granulomatosis and a severe cutaneous eruption in association with
MER
therapy. The toxicities of BCG and
MER
therapy were compared with the pathogenesis of granuloma formation reviewed. This patient's complications were consistent with a hypersensitivity reaction to
MER
.
Pulmonary granulomatosis
and rash must be added to the list of known
MER
toxicities.
...
PMID:Systemic complications of MER immunotherapy of cancer: pulmonary granulomatosis and rash. 42 Nov 77
